Larimar Therapeutics Inc

LRMR

Company Profile

  • Business description

    Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

  • Contact

    Three Bala Plaza East
    Suite 506
    Bala CynwydPA19004
    USA

    T: +1 844 511-9056

    https://www.larimartx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    65

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,637.8012.900.15%
CAC 407,779.728.38-0.11%
DAX 4023,933.23104.96-0.44%
Dow JONES (US)42,101.562.860.01%
FTSE 1008,716.459.56-0.11%
HKSE23,573.38315.071.35%
NASDAQ19,208.79107.850.56%
Nikkei 22538,432.98710.581.88%
NZX 50 Index12,281.3180.95-0.65%
S&P 5005,908.8120.260.34%
S&P/ASX 2008,409.8012.900.15%
SSE Composite Index3,363.4523.510.70%

Market Movers